Navigation Links
MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
Date:4/12/2011

MOUNTAIN VIEW, Calif., April 12, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present new data from two safety studies of LEVADEX® orally inhaled migraine drug.  The data will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii April 9-16, 2011.  LEVADEX is an investigational acute drug for migraine that has completed Phase 3 clinical development.

Findings to be presented at 2:00 p.m. HAST today in the poster titled "An Open-Label, 2-Period, Crossover Study Comparing the Pharmacokinetics and Tolerability of LEVADEX (MAP0004, Orally Inhaled DHE) and Intravenous DHE (DHE45) in Smoking and Non-Smoking Adult Volunteers," show that:

  • LEVADEX exposure was not higher in smokers, potentially due to reduced pulmonary absorption
  • LEVADEX was quickly absorbed into the bloodstream of both smokers and non-smokers, as evidenced by a median Tmax of 4.98 and 7.02 minutes respectively
  • The mean half-life for LEVADEX was similar for smokers (16.1 hours) and non-smokers (14.5 hours) and was similar to IV DHE administration (13.3 hours for smokers and 12.4 hours for non-smokers)
  • Tolerability of LEVADEX was similar in smokers and non-smokers

  • Findings in a separate safety study to be presented at 2:00 p.m.  HAST today in the poster titled "A Randomized, Double-Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of LEVADEX (MAP0004, Orally Inhaled DHE) and Intravenous DHE on Pulmonary Arterial Systolic Pressure," show that:

  • Neither LEVADEX, IV DHE nor placebo produced clinically significant changes in pulmonary arterial systolic pressure (PASP) or other cardiac functions; however a statistically higher elevation of PASP was found following IV DHE treatment compared to the LEVADEX and placebo tr
    '/>"/>

  • SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... ATLANTA , May 21, 2015  CryoLife, Inc. ... tissue processing company focused on cardiac and vascular surgery, ... a quarterly cash dividend for the second quarter 2015 ... quarterly cash dividend of $0.03 per share will be ... of record as of June 12, 2015.  The ex-dividend ...
    (Date:5/21/2015)... CAMBRIDGE, England , May 21, ... zur Bekämpfung von Arzneimittelfälschungen - Zwecks ... eines Arzneimittelprüfdienstes wird auf EG-Mitgliedstaaten verwiesen, ... Pilotsysteme betrieben werden.  Wählen Sie ein ... Bei der Richtlinie zur Bekämpfung von ...
    (Date:5/21/2015)... , May 21, 2015 Northwest Biotherapeutics, ... company developing DCVax® personalized immune therapies for cancer, announced ... Technical Officer of the Company, will be making a ... on Emerging Approaches to Immunotherapy at 11:40 a.m. on May ... York City . Dr. Bosch,s ...
    Breaking Medicine Technology:CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3NW Bio To Present At New York Academy Of Sciences' Conference On Emerging Approaches To Immunotherapy 2NW Bio To Present At New York Academy Of Sciences' Conference On Emerging Approaches To Immunotherapy 3
    ... 2011 First results from a large-scale Phase III ... New England Journal of Medicine (NEJM) , show the ... significant protection against clinical and severe malaria with an ... today at the Malaria Forum hosted by the Bill ...
    ... 2011 Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee ... ("Epix") announced today that the S1P1 lead compounds, AMG ... 2011 in a sealed bid sale.  S1P1 agonists are ... MS is the second most common cause of ...
    Cached Medicine Technology:First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 2First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 3First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 4First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 5First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 6First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 7First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 8S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis 2
    (Date:5/22/2015)... (PRWEB) May 22, 2015 In April ... In the past 9 years they have concentrated their ... United States and Canada. Because of this growth and ... established corporate offices in Denver, Colorado, Cleveland, Ohio, Houston, ... specializes in opening new dental offices, dental start ups, ...
    (Date:5/22/2015)... A new program for the "In America" television series ... Therapy. , James Earl Jones will host the ... therapy and discusses how the exercises can decrease pain ... ailments and injuries. Physical therapists work with their ... daily activities such as house cleaning and shopping, work ...
    (Date:5/22/2015)... Maine (PRWEB) May 22, 2015 ... single-use swabs for the medical, diagnostic, environmental, and ... entire line of products in the US. At ... their operations outside the US, Puritan remains committed ... products at their Guilford, Maine facility. , Since ...
    (Date:5/22/2015)... May 22, 2015 Yisrayl Hawkins, Pastor and ... released a new letter calling on religious leaders to make ... which was published on his blog, discusses the history of ... needed to stop it. Yisrayl says mankind was created to ... experienced in today’s society. , “Yahweh created mankind, according ...
    (Date:5/22/2015)... May 22, 2015 Pro3rd Impression ... designed exclusively for Final Cut Pro X. Pro3rd Impression's ... design. , Intuitive on-screen-controls allow users to customize ... Reflections, colors, layouts, and much more can be edited ... , Pro3rd Impression comes packed with 30 ...
    Breaking Medicine News(10 mins):Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2
    ... shown that it seems to stop mice with the ... such vaccines could delay or prevent similar symptoms in ... deposits in mouse brains -the other major indicator of ... Ireland, is poised to begin human clinical trails of ...
    ... to test the importance of sleep for memory and ... effects, such as fatigue and reduced alertness. ... complications by allowing recovery sleep by Harvard Medical school ... day showed no improvement in task performance but those ...
    ... were 16 years old and the men were 13.5 years ... ,It appears that the sexual abuse or assault was ... thyroid diseases. It varied by gender, where arthritis and breast ... occur in men. ,There is an association between ...
    ... be remembered as one of the most controversial presidents ever. ... history to be impeached by the House of Representatives. Only ... save himself and his country further damage. ,He has ... and his mid east peace efforts have always come unstuck ...
    ... concluded Indian science congress in New Delhi have called for ... iron fortification of crops. Almost 50% of women and 75% ... While iron supplementation is expensive, fortification of plants with iron ... is fairly cheaper, scientists say. ,This idea has found ...
    ... scientists revealed that two antioxidants in black pepper and ... the bacterial DNA from damage by irradiation in test ... effect and protecting organisms like Escherichia role and Bacillus ... ,The study offers hope for the development of ...
    Cached Medicine News:
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: